0:00
welcome back to our Channel today we're
0:02
discussing some groundbreaking news in
0:04
HIV treatment Gilead Sciences and MC
0:07
recently announced exciting results from
0:08
a phase 2 trial of a new investigational
0:13
treatment this development could mean a
0:15
significant shift in the way HIV is
0:18
managed traditionally HIV treatment
0:21
involves daily medication which can be
0:23
challenging for some people the new
0:25
combination therapy being tested by
0:27
Gilead and MC uses two powerful
0:29
compounds I travier and Len
0:31
kavir these two work together each
0:34
targeting HIV differently to keep the
0:38
control here's what happened in their
0:39
recent Phase 2 study by week 48 94.2% of
0:44
the participants on the new Once weekly
0:46
regimen had a viral load below 50 copies
0:48
per milliliter a key indicator that the
0:50
virus was effectively
0:52
suppressed for context no participant
0:55
had a viral load Above This threshold
0:57
showing promising consistency for this
1:01
so what exactly are islatravir and Len
1:05
papaver Len capir is a unique
1:08
anti-retroviral drug that works in
1:10
multiple stages of the HIV life cycle
1:13
which allows it to be effective even
1:14
against strains of the virus that have
1:16
developed resistance to other
1:18
treatments in 2022 a twice-yearly
1:21
injectable version called Sun Lena was
1:23
approved for individuals with multi-drug
1:25
resistant HIV this long- acting
1:27
injection has also shown strong results
1:29
as is a pre-exposure prophylaxis prep
1:31
for both cisgender women and for gay
1:34
bisexual and gender diverse people
1:36
Gilead offers Lop ofier in a pill form
1:39
for initial treatment which can also act
1:41
as a temporary substitute if a scheduled
1:45
missed islatravir also known as FDA or
1:50
8591 is a novel type of drug called a
1:52
nucleoside reverse transcript
1:54
translocation inhibitor it's shown
1:56
strong effects in combination with
1:58
dorine py filtro helping m maintain
2:00
viral suppression in individuals who
2:03
treatments its long Half-Life makes it
2:05
suitable for long acting treatment and
2:09
options in a statement Dr Jared baon
2:12
from Gilead highlighted that this weekly
2:14
regimen is a step toward making HIV
2:16
treatment more person- centered allowing
2:18
options that better fit individual
2:20
Lifestyles doctor Elizabeth re from Merc
2:24
also emphasized that once weekly dosing
2:26
could improve treatment adherence and
2:30
development of the investigational drug
2:32
isolater faced a setback in 2021 when
2:35
clinical trials revealed concerning side
2:38
effects participants living with HIV in
2:41
treatment trials showed a drop in cd4t
2:43
cell counts while HIV negative
2:45
Volunteers in prevention studies
2:47
experienced a decrease in total
2:49
lymphocyst this led the FDA to place a
2:52
clinical hold on the drug following an
2:55
in-depth review MC scientists concluded
2:57
that these issues were likely due to
2:59
high dosing levels the FDA lifted the
3:01
hold allowing MC to resume studies using
3:04
a lower dose of ice latra in combination
3:06
with other drugs however its development
3:11
halted a phase I I trial examined a once
3:14
weekly combination of israir with Len
3:17
kavir enrolling 104 virologically
3:20
suppressed adults previously on daily
3:21
big tarvi with high viral suppression
3:24
rates and stable immune cell counts
3:26
participants were randomly assigned to
3:28
continue bigar or switch to Once weekly
3:31
islatravir 2 mg and Len kavir 300
3:35
mg after 24 weeks viral suppression
3:38
remained consistent across both groups
3:41
94.2% and by 48 weeks the islatravir and
3:44
Len cap Air Group maintain the same
3:46
suppression rate with no participants
3:48
experiencing a viral load above 50
3:52
ml the safety profile was positive 19.2%
3:56
of participants in the weekly regimen
3:57
group and 5.8% in the big tarvey group
4:00
reported mild to moderate side effects
4:03
common symptoms included dry mouth and
4:05
nausea with no severe CD4 or lymy count
4:09
decreases these findings support the
4:12
potential of islatravir and Lenape as a
4:14
once-weekly oral treatment for HIV a
4:17
fixed dose combination pill is now being
4:19
tested in Phase I I trials Island 1 and
4:22
2 Dr Jared baon from Gilead again
4:25
highlighted the importance of person-
4:27
centered long acting HIV treatment
4:29
options that cater to individual needs
4:31
noting the goal of providing varied
4:33
effective options for people living with
4:36
HIV now let's talk about side
4:39
effects in the trial some participants
4:42
on the new regimen experienced mild side
4:44
effects like dry mouth and nausea these
4:47
effects were relatively rare and mild
4:50
and none of the participants experienced
4:51
severe adverse effects two people did
4:55
discontinue the regimen but for reasons
4:57
unrelated to the treatment
5:00
these findings are not just about
5:01
numbers for people living with HIV a
5:04
weekly pill could mean fewer reminders
5:06
of their condition greater convenience
5:08
and possibly even better long-term
5:11
adherence and this study marks just the
5:13
beginning phase three trials are next to
5:15
confirm these findings on a larger
5:18
scale Gilead and Mark's Work is part of
5:21
a larger Trend in HIV research focused
5:23
on Long acting treatments including
5:25
injections and other delivery methods
5:27
the aim to provide options that fit the
5:30
unique needs of every person with HIV
5:33
ultimately helping to end the epidemic
5:36
everyone thank you for tuning in to
5:38
learn about this exciting development in
5:39
HIV treatment and as always don't forget
5:42
to like subscribe and hit the Bell icon
5:45
for more updates on breakthroughs in
5:46
health see you next time
